| scholarly article | Q13442814 |
| P50 | author | Jose Garnacho-Montero | Q56867748 |
| Jose Luis Garcia Garmendia | Q71475964 | ||
| P2093 | author name string | Barrero-Almodóvar AE | |
| Jiménez-Jiménez FJ | |||
| Ortiz-Leyba C | |||
| Bernabeu-WittelI M | |||
| Gallego-Lara SL | |||
| Madrazo-Osuna J | |||
| P2860 | cites work | APACHE II: a severity of disease classification system | Q29547729 |
| Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis | Q33926652 | ||
| Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study | Q34088730 | ||
| Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii | Q34109543 | ||
| Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. | Q34128899 | ||
| Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy | Q34233910 | ||
| Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin | Q35533543 | ||
| Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus | Q39411514 | ||
| A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting | Q39536779 | ||
| Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients | Q42068129 | ||
| Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial | Q43609282 | ||
| Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii | Q43705318 | ||
| Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay | Q43798721 | ||
| Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System | Q44727502 | ||
| Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. | Q54043075 | ||
| Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. | Q54175715 | ||
| The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia | Q57238120 | ||
| Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients | Q59235137 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Acinetobacter baumannii | Q3241189 |
| pneumonia | Q12192 | ||
| multiple drug resistance | Q643839 | ||
| ventilator | Q813243 | ||
| P304 | page(s) | 1111-1118 | |
| P577 | publication date | 2003-04-14 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP | |
| P478 | volume | 36 |
| Q90283255 | A Study of Multidrug-Resistant, Colistin-Only-Sensitive Infections in Intubated and Mechanically Ventilated Patients Over 2 Years |
| Q21131083 | A new strategy to fight antimicrobial resistance: the revival of old antibiotics |
| Q38501685 | A review on colistin nephrotoxicity |
| Q89507355 | Acinetobacter baumannii Gastrointestinal Colonization Is Facilitated by Secretory IgA Which Is Reductively Dissociated by Bacterial Thioredoxin A |
| Q36575078 | Acinetobacter baumannii Is Dependent on the Type II Secretion System and Its Substrate LipA for Lipid Utilization and In Vivo Fitness |
| Q42255792 | Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years |
| Q44936182 | Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings |
| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q27015109 | Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options |
| Q37037407 | Acinetobacter pneumonia: a review. |
| Q40290852 | Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem |
| Q42056256 | Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration |
| Q84675360 | Aerosolized Colistin for the Treatment of Multidrug-resistant Acinetobacter baumannii Pneumonia: Experience in a Tertiary Care Hospital in Northern Taiwan |
| Q24802737 | Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis |
| Q28257612 | An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii |
| Q26796605 | Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review |
| Q33732524 | Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections |
| Q42908865 | Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia |
| Q26739860 | Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). |
| Q37544333 | Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. |
| Q37838126 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? |
| Q89719222 | Challenges in the Diagnosis and Management of Bacterial Lung Infections in Solid Organ Recipients: A Narrative Review |
| Q36172505 | Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design |
| Q90398183 | Clinical Outcomes Of Colistin In Combination With Either 6-G Sulbactam Or Carbapenems For The Treatment Of Extensively Drug-Resistant Acinetobacter Baumannii Pneumonia With High MIC To Sulbactam, A Prospective Cohort Study |
| Q62487254 | Clinical and laboratory-induced colistin-resistance mechanisms in Acinetobacter baumannii |
| Q38414785 | Clinical efficacy and safety of colistin treatment in patients with pulmonary infection caused by Pseudomonas aeruginosa or Acinetobacter baumannii: a meta-analysis |
| Q47137686 | Clinical experiment with the use of colistin for the treatment of multiresistant Acinetobacter baumanii nosocomial infection |
| Q37029217 | Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults |
| Q92546679 | Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service |
| Q46142029 | Colistin : renaissance of an old antibiotic? |
| Q43179104 | Colistin administration to pediatric and neonatal patients |
| Q41871984 | Colistin and polymyxin B: a re-emergence |
| Q44696156 | Colistin for Klebsiella pneumoniae-associated sepsis |
| Q28082041 | Colistin for lung infection: an update |
| Q24673399 | Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients |
| Q40069157 | Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients? |
| Q53838114 | Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study. |
| Q84941144 | Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia |
| Q38048852 | Colistin: an update on the antibiotic of the 21st century |
| Q40672610 | Colistin: the phoenix arises |
| Q34560321 | Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections |
| Q36095874 | Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections |
| Q46929397 | Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study |
| Q38232199 | Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date |
| Q33938143 | Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis |
| Q36427137 | Comparative Genomics of Two ST 195 Carbapenem-Resistant Acinetobacter baumannii with Different Susceptibility to Polymyxin Revealed Underlying Resistance Mechanism |
| Q50082670 | Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. |
| Q42256268 | Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia |
| Q53871945 | Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. |
| Q53802828 | Conditional probability analysis of multidrug resistance in Gram-negative bacilli isolated from tertiary medical institutions in South Korea during 1999-2009. |
| Q35745242 | Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists |
| Q36908744 | Consensus document on nosocomial pneumonia |
| Q37330689 | Current control and treatment of multidrug-resistant Acinetobacter baumannii infections |
| Q37319452 | Defining, treating and preventing hospital acquired pneumonia: European perspective |
| Q34109281 | Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection |
| Q37809382 | Discovering new antimicrobial agents |
| Q90985629 | Does open or closed endotracheal suction affect the incidence of ventilator associated pneumonia in the intensive care unit? A systematic review |
| Q34601684 | Drug treatment for multidrug-resistant Acinetobacter baumannii infections. |
| Q36322542 | Early prosthetic valve endocarditis due to Acinetobacter baumannii: a case report and brief review of the literature |
| Q43124623 | Effectiveness and safety of colistin: prospective comparative cohort study |
| Q35101242 | Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis |
| Q28539496 | Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis |
| Q37120088 | Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models. |
| Q39894808 | Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa |
| Q33676191 | Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii |
| Q83450247 | Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains |
| Q43150667 | Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. |
| Q51330262 | Electrophysiology and ultrastructural changes in mouse sciatic nerve associated with colistin sulfate exposure. |
| Q42758854 | Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India |
| Q36487901 | Endogenous pulmonary antibiotics |
| Q47952826 | Evaluation of colistin nephrotoxicity administered at different doses in the rat model |
| Q38961737 | Expert synthesis of the literature to support critical care decision making |
| Q57167678 | First report of colistin resistance among carbapenem-resistant isolates recovered from hospitalized patients in Egypt |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q37869910 | Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. |
| Q37709735 | Global survey of polymyxin use: A call for international guidelines |
| Q22241905 | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia |
| Q37013020 | Healthcare-associated pneumonia: principles and emerging concepts on management |
| Q41992993 | High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial |
| Q35977417 | High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. |
| Q92302843 | History, Chemistry and Antibacterial Spectrum |
| Q36548708 | Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care |
| Q35457068 | How to treat VAP due to MDR pathogens in ICU patients |
| Q47112723 | Illustrative examples of probable transfer of resistance determinants from food animals to humans: Streptothricins, glycopeptides, and colistin |
| Q36165152 | Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study |
| Q42277755 | Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality |
| Q37409893 | In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. |
| Q37915360 | Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. |
| Q37983920 | Inhaled colistin for lower respiratory tract infections. |
| Q33389073 | Insight into the microbial multicellular lifestyle via flow-cell technology and confocal microscopy |
| Q90362523 | Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen |
| Q46153446 | Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection |
| Q46516945 | Intravenous colistimethate for multidrug-resistant Gram-negative bacteria |
| Q24651466 | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
| Q40707401 | Inverse PCR for subtyping of Acinetobacter baumannii carrying ISAba1. |
| Q38058355 | Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens |
| Q36078359 | Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society |
| Q83390539 | Management of antimicrobial use in the intensive care unit |
| Q38623310 | Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations |
| Q92302883 | Meta-analysis of Polymyxin Use in Patients |
| Q36310173 | Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection |
| Q36773761 | Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology |
| Q64268095 | Molecular Mechanisms of Colistin-Induced Nephrotoxicity |
| Q46198938 | Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. |
| Q41718510 | Multi-drug resistant Acinetobacter ventilator-associated pneumonia |
| Q33626986 | Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital |
| Q89068708 | Multidrug-Resistant Acinetobacter baumannii Chloramphenicol Resistance Requires an Inner Membrane Permease |
| Q40845430 | Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit |
| Q35848861 | Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians |
| Q35002302 | Multidrug-resistant Gram-negative infections: what are the treatment options? |
| Q36657841 | Multidrug-resistant organisms in military wounds from Iraq and Afghanistan |
| Q43097126 | Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa |
| Q36667079 | Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients |
| Q37636150 | New information about the polymyxin/colistin class of antibiotics |
| Q36894462 | Non-fermentative Gram-negative bacteria |
| Q43756833 | Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital |
| Q38416932 | Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia |
| Q24794555 | Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria |
| Q43870052 | Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series |
| Q40494723 | Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections |
| Q33935368 | Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. |
| Q44808038 | Pharmacokinetics of intravenous polymyxin B in critically ill patients. |
| Q39615925 | Place of Colistin-Rifampicin Association in the Treatment of Multidrug-Resistant Acinetobacter Baumannii Meningitis: A Case Study |
| Q36612595 | Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. |
| Q36786226 | Polymyxin antibiotics for gram-negative infections |
| Q37215935 | Polymyxins revisited |
| Q82669474 | Polymyxins: old antibiotics are back |
| Q35623068 | Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications |
| Q43249112 | Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. |
| Q37058361 | Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms |
| Q41038831 | Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii |
| Q27499294 | Renal and neurological side effects of colistin in critically ill patients |
| Q35541277 | Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing |
| Q64936099 | Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus. |
| Q37263364 | Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections |
| Q39167614 | Risk of Mortality of Catheter-Related Bloodstream Infections Caused by Acinetobacter Species. |
| Q40986687 | Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis |
| Q33416170 | Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections |
| Q80387733 | Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study |
| Q46571062 | Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study |
| Q35218683 | Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study proto |
| Q42546631 | Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock |
| Q43983010 | Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin |
| Q41445964 | Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex |
| Q40965515 | Task force on management and prevention of Acinetobacter baumannii infections in the ICU. |
| Q36382140 | The epidemiology and control of Acinetobacter baumannii in health care facilities |
| Q36750086 | The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections |
| Q35139454 | The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. |
| Q34652418 | The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature |
| Q37099006 | Therapeutic options for Acinetobacter baumannii infections |
| Q38049332 | Therapeutic options for Acinetobacter baumannii infections: an update |
| Q34303970 | Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens |
| Q34757004 | Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes |
| Q24798835 | Toxicity after prolonged (more than four weeks) administration of intravenous colistin |
| Q92302910 | Toxicity in Patients |
| Q21092897 | Toxicity of polymyxins: a systematic review of the evidence from old and recent studies |
| Q37704397 | Treatment of Acinetobacter infections |
| Q35183740 | Treatment of Acinetobacter spp infections |
| Q38185648 | Treatment of multidrug-resistant Gram-negative infections in children |
| Q26991886 | Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections |
| Q37058001 | Treatment options for multidrug-resistant Acinetobacter species |
| Q36607401 | Treatment options for multidrug-resistant bacteria. |
| Q37145741 | Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa |
| Q41281850 | Variables determining the development of colistin-associated renal impairment |
| Q64027934 | Ventilator-Associated Pneumonia due to Drug-Resistant : Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality |
| Q26999921 | What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression |
| Q37907967 | When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock |
| Q36399486 | Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury |
| Q80972312 | [Recommendations for the treatment of severe nosocomial pneumonia] |
Search more.